4583 Stock Overview
Engages in the research and development of drug discovery technology platforms worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Chiome Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥269.00 |
| 52 Week High | JP¥304.00 |
| 52 Week Low | JP¥75.00 |
| Beta | 0.66 |
| 1 Month Change | 29.95% |
| 3 Month Change | 120.49% |
| 1 Year Change | 99.26% |
| 3 Year Change | 37.95% |
| 5 Year Change | 36.55% |
| Change since IPO | -8.43% |
Recent News & Updates
Is Chiome Bioscience (TSE:4583) Weighed On By Its Debt Load?
Nov 21
Is Chiome Bioscience (TSE:4583) Using Too Much Debt?
Jun 28Shareholder Returns
| 4583 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 9.8% | 2.5% | 2.1% |
| 1Y | 99.3% | -11.9% | 15.6% |
Return vs Industry: 4583 exceeded the JP Life Sciences industry which returned -11.3% over the past year.
Return vs Market: 4583 exceeded the JP Market which returned 16.3% over the past year.
Price Volatility
| 4583 volatility | |
|---|---|
| 4583 Average Weekly Movement | 20.7% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4583's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4583's weekly volatility has increased from 14% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shigeru Kobayashi | www.chiome.co.jp |
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies.
Chiome Bioscience Inc. Fundamentals Summary
| 4583 fundamental statistics | |
|---|---|
| Market cap | JP¥16.80b |
| Earnings (TTM) | -JP¥1.22b |
| Revenue (TTM) | JP¥581.07m |
28.9x
P/S Ratio-13.8x
P/E RatioIs 4583 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4583 income statement (TTM) | |
|---|---|
| Revenue | JP¥581.07m |
| Cost of Revenue | JP¥269.92m |
| Gross Profit | JP¥311.15m |
| Other Expenses | JP¥1.53b |
| Earnings | -JP¥1.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -19.49 |
| Gross Margin | 53.55% |
| Net Profit Margin | -209.45% |
| Debt/Equity Ratio | 24.9% |
How did 4583 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:28 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chiome Bioscience Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |